share_log

LevelJump Healthcare Corp. Announces Record Revenues; Q2 Revenue Increase of 34%

LevelJump Healthcare Corp. Announces Record Revenues; Q2 Revenue Increase of 34%

LevelJump Healthcare Corp. 宣佈創紀錄的收入;第二季度收入增長
newsfile ·  2023/08/29 17:00

Toronto, Ontario--(Newsfile Corp. - August 29, 2023) - LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("LevelJump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce today it has reported financial results for the fiscal quarter ended June 30, 2023. All amounts are expressed in Canadian dollars.

安大略省多倫多-(Newsfile Corp.-2023年8月29日)-加拿大B2B遠端醫療解決方案領先企業LevelJump Healthcare Corp.(TSXV:JUMP)(OTCQB:JMPHF)(FSE:75J)(“LevelJump”或“公司”)今天高興地宣佈,公司已公佈截至2023年6月30日的財季財務業績。所有金額均以加元表示。

Financial and Operational Highlights

財務和運營亮點

  • Revenues from Canadian Teleradiology Services, Inc. ("CTS") operations hits record level with $3,122,046 in revenues for the second quarter.

  • Gross profit from CTS operations was $912,353 for the quarter, a 29% margin (2% increase from margins in Q1 2023).

  • CTS Year over Year Q2 revenue increased 34%.

  • 加拿大Teleradiology Services,Inc.(“CTS”)業務第二季度的收入達到創紀錄的3122,046美元。

  • 該季度來自CTS業務的毛利潤為912,353美元,利潤率為29%(比2023年第一季度利潤率增長2%)。

  • CTS第二季度收入同比增長34%。

Management Comments

管理意見

"We had another record quarter of revenue and are now tracking over $12 million annually in revenues," said Mitch Geisler CEO. "As our Yonge Sheppard location comes online, and once we close the Alberta acquisition, we expect revenues to grow to over $20 million annually with a margin of over 30%, and the Company's EBITDA to be healthy and consistently positive."

該公司首席執行官米奇·蓋斯勒表示:“我們的季度營收再創新高,現在的年營收超過1200萬美元。”隨著我們的Yonge Seppard分店上線,一旦我們完成對艾伯塔省的收購,我們預計年收入將增長到2000萬美元以上,利潤率超過30%,公司的EBITDA將保持健康和持續積極的狀態。“

Non-IFRS Financial Measures

非國際財務報告準則財務衡量標準

This news release contains financial terms (such as adjusted EBITDA) that are not considered in IFRS. Such financial measures, together with measures prepared in accordance with IFRS, provide useful information to investors and shareholders, as management uses them to evaluate the operating performance of the Company. The Company's determination of these non-IFRS measures may differ from other reporting issuers, and therefore are unlikely to be comparable to similar measures presented by other companies. Further, these non-IFRS measures should not be considered in isolation or as a substitute for measures of performance or cash flows prepared in accordance with IFRS. These financial measures are included because management uses this information to analyze operating performance and liquidity.

本新聞稿包含IFRS中未考慮的財務術語(如調整後的EBITDA)。該等財務措施,連同根據國際財務報告準則編制的措施,為投資者和股東提供有用的資訊,因為管理層利用這些措施來評估公司的經營業績。該公司對這些非國際財務報告準則衡量標準的確定可能與其他報告發行人不同,因此不太可能與其他公司提出的類似衡量標準相比較。此外,不應孤立地考慮這些非《國際財務報告準則》的衡量標準,也不應將其作為根據《國際財務報告準則》編制的業績衡量標準或現金流的替代指標。這些財務指標之所以包括在內,是因為管理層使用這些資訊來分析經營業績和流動性。

Adjusted EBITDA & Annual Revenue Run Rate

調整後的EBITDA和年度收入運行率

Management believes adjusted EBITDA is a useful supplemental measure to determine the Company's ability to generate cash available for working capital, capital expenditures, debt repayments, interest expense and income taxes.

管理層認為,調整後的EBITDA是確定公司產生可用於營運資本、資本支出、債務償還、利息支出和所得稅的現金能力的有用補充指標。

EBITDA refers to net income (loss) determined in accordance with IFRS, before depreciation and amortization, net interest expense (income) and income tax expense (recovery). The Company defines adjusted EBITDA as EBITDA, plus stock-based compensation expense, restructuring, fair value adjustments, listing expense and transaction costs, impairment and finance income.

EBITDA指按照國際財務報告準則確定的未計折舊和攤銷前的淨收益(虧損)、淨利息支出(收入)和所得稅支出(回收)。本公司將調整後的EBITDA定義為EBITDA,加上基於股票的薪酬支出、重組、公允價值調整、上市費用和交易成本、減值和財務收入。

A reconciliation of adjusted EBITDA to net income (loss) is as follows:

調整後的EBITDA與淨收益(虧損)的對賬如下:

Three Months ended
June 30
Six Months ended
June 30
($ in thousands) 2023 2022 2023 2022
Net and comprehensive income (loss) (237 ) (184 ) (445 ) (527 )
Add back:
Depreciation and amortization 120 53 212 94
Net interest expense 61 36 117 60
Stock-based compensation - 37 - 220
Taxes - - 9 -
Misc and foreign exchange (114 ) 1 (116 ) (86 )
EBITDA (170 ) (57 ) (223 ) (239 )
Add back:
Broker commissions for financing 67 20 67 20
One-time Professional Fees related to Acquisitions 20 175 100 250
Adjusted EBITDA (83 ) 138 (56 ) 31
截至三個月
6月30日
截至六個月
6月30日
(千美元) 2023年年 2022 2023年年 2022
淨收益和綜合收益(虧損) (237 ) (184) ) (445) ) (527) )
添加回:
折舊及攤銷 120 53 212 94
淨利息支出 61 36 117 60
基於股票的薪酬 - 37 - 220
稅費 - - 9. -
MISC與外匯 (114) ) 1 (116) ) (86 )
EBITDA (170 ) (57) ) (223 ) (239 )
添加回:
融資的經紀佣金 67 20個 67 20個
與收購相關的一次性專業費用 20個 一百七十五 100個 250個
調整後的EBITDA (83) ) 一百三十八 (56) ) 31

About LevelJump Healthcare
LevelJump Healthcare Corp., (TSXV: JUMP) provides telehealth solutions to client hospitals and imaging centers through its Teleradiology division, as well as in person radiology services through its IHF's (Independent Healthcare Facilities). JUMP focuses primarily on critical care for urgent and emergency patients, establishing integral relationships in the communities we serve.

關於LevelJump Healthcare
LevelJump Healthcare Corp.(多倫多證券交易所股票代碼:JUMP)通過其遠端放射部門為客戶醫院和成像中心提供遠端醫療解決方案,並通過其IHF(獨立醫療設施)提供面對面的放射服務。JUMP主要專注於緊急和緊急患者的危重護理,在我們所服務的社區中建立完整的關係。

ON BEHALF OF THE BOARD OF DIRECTORS OF
LEVELJUMP HEALTHCARE CORP.

我謹代表華為的董事會
LEVELJUMP醫療保健公司。

Mitchell Geisler
Chief Executive Officer

米切爾·蓋斯勒
首席執行官

Caitlin-Robyn Densmore
Investor Relations Manager
Caitlin.Densmore@leveljumphealthcare.com
(437) 214-1568

凱特琳-羅賓·丹斯莫爾
投資者關係經理
郵箱:Caitlin.Densmore@Levjumphelthare.com
(437)214-1568

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business plans and the outlook of the Company's industry. Although the Company believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this release and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by applicable securities laws. The Company undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Company, Canadian Teleradiology Services, Inc., their securities, or their respective financial or operating results (as applicable).

關於前瞻性資訊的警示聲明
本新聞稿包含與公司業務計劃和公司行業前景相關的適用證券法所指的“前瞻性資訊”。儘管本公司認為,根據其高級管理人員和董事的經驗、當前狀況和預期未來發展以及其他被認為合適的因素,這些前瞻性資訊中反映的預期是合理的,但不應過度依賴這些預期,因為本公司不能保證這些預期將被證明是正確的。實際結果和發展可能與這些陳述中預期的大不相同。本新聞稿中的陳述是截至本新聞稿發佈之日作出的,公司不承擔任何責任對其進行更新或修改,以反映除適用證券法所要求的以外的新事件或新情況。本公司沒有義務對第三方對本公司、加拿大TelerRadiology Services,Inc.、其證券或其各自的財務或經營業績(如適用)所作的分析、預期或陳述發表評論。

Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

交易所及其監管服務提供商(該術語在交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。

The securities being offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor in any other jurisdiction.

所發行的證券尚未、也不會根據修訂後的《1933年美國證券法》(下稱《美國證券法》)或美國任何州證券法進行註冊,在未進行註冊或未獲得美國證券法和適用的美國州證券法的註冊要求豁免的情況下,不得在美國境內或向美國人、為美國個人或為美國人的利益進行發行或銷售。本新聞稿不構成在美國或其他任何司法管轄區出售證券的要約或購買證券的要約。

To view the source version of this press release, please visit

要查看本新聞稿的源版本,請訪問

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論